China National Medicines Future Growth
Future criteria checks 1/6
China National Medicines is forecast to grow earnings and revenue by 11.4% and 10.1% per annum respectively. EPS is expected to grow by 11.3% per annum. Return on equity is forecast to be 13.7% in 3 years.
Key information
11.4%
Earnings growth rate
11.3%
EPS growth rate
Healthcare earnings growth | 22.1% |
Revenue growth rate | 10.1% |
Future return on equity | 13.7% |
Analyst coverage | Low |
Last updated | 24 Aug 2024 |
Recent future growth updates
Recent updates
Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)
Sep 10Returns On Capital At China National Medicines (SHSE:600511) Paint A Concerning Picture
Jul 28China National Medicines Corporation Ltd.'s (SHSE:600511) Low P/E No Reason For Excitement
Jun 24China National Medicines (SHSE:600511) Has Announced That It Will Be Increasing Its Dividend To CN¥0.854
Jun 07Is China National Medicines (SHSE:600511) Using Too Much Debt?
Jun 05Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)
May 21Capital Allocation Trends At China National Medicines (SHSE:600511) Aren't Ideal
Apr 10China National Medicines (SHSE:600511) Could Easily Take On More Debt
Feb 28Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 64,974 | 2,897 | N/A | 2,820 | 4 |
12/31/2025 | 59,149 | 2,616 | N/A | 2,324 | 5 |
12/31/2024 | 53,966 | 2,382 | N/A | 1,949 | 4 |
6/30/2024 | 50,312 | 2,162 | 1,688 | 1,827 | N/A |
3/31/2024 | 50,592 | 2,191 | 2,008 | 2,151 | N/A |
12/31/2023 | 49,696 | 2,146 | 2,582 | 2,727 | N/A |
9/30/2023 | 47,486 | 1,995 | 2,466 | 2,602 | N/A |
6/30/2023 | 47,632 | 2,086 | 2,040 | 2,194 | N/A |
3/31/2023 | 45,665 | 2,005 | 2,429 | 2,560 | N/A |
12/31/2022 | 45,499 | 1,964 | 2,265 | 2,395 | N/A |
9/30/2022 | 46,719 | 1,884 | 1,336 | 1,460 | N/A |
6/30/2022 | 46,399 | 1,850 | 1,081 | 1,185 | N/A |
3/31/2022 | 47,185 | 1,830 | 1,746 | 1,851 | N/A |
12/31/2021 | 46,469 | 1,754 | 1,862 | 1,957 | N/A |
9/30/2021 | 45,559 | 1,680 | 1,085 | 1,170 | N/A |
6/30/2021 | 44,923 | 1,529 | 1,129 | 1,197 | N/A |
3/31/2021 | 42,512 | 1,449 | 1,187 | 1,247 | N/A |
12/31/2020 | 40,379 | 1,383 | 1,233 | 1,302 | N/A |
9/30/2020 | 41,046 | 1,537 | 1,058 | 1,125 | N/A |
6/30/2020 | 41,153 | 1,469 | 1,922 | 1,997 | N/A |
3/31/2020 | 42,805 | 1,549 | 1,399 | 1,477 | N/A |
12/31/2019 | 44,644 | 1,604 | 1,690 | 1,776 | N/A |
9/30/2019 | 42,673 | 1,525 | 1,037 | 1,139 | N/A |
6/30/2019 | 40,991 | 1,523 | 1,024 | 1,159 | N/A |
3/31/2019 | 39,659 | 1,436 | -33 | 103 | N/A |
12/31/2018 | 38,740 | 1,404 | 849 | 982 | N/A |
9/30/2018 | 37,994 | 1,256 | 2,457 | 2,576 | N/A |
6/30/2018 | 37,452 | 1,224 | 1,977 | 2,058 | N/A |
3/31/2018 | 36,653 | 1,163 | N/A | 1,424 | N/A |
12/31/2017 | 36,285 | 1,141 | N/A | 1,074 | N/A |
9/30/2017 | 36,072 | 1,060 | N/A | 63 | N/A |
6/30/2017 | 35,540 | 1,044 | N/A | -85 | N/A |
3/31/2017 | 40,103 | 1,101 | N/A | 488 | N/A |
12/31/2016 | 34,611 | 990 | N/A | 1,043 | N/A |
9/30/2016 | 28,613 | 887 | N/A | 461 | N/A |
6/30/2016 | 22,813 | 752 | N/A | 716 | N/A |
3/31/2016 | 12,408 | 527 | N/A | 445 | N/A |
12/31/2015 | 12,078 | 513 | N/A | 440 | N/A |
9/30/2015 | 12,065 | 499 | N/A | 307 | N/A |
6/30/2015 | 11,894 | 499 | N/A | 424 | N/A |
3/31/2015 | 11,773 | 490 | N/A | 394 | N/A |
12/31/2014 | 11,538 | 483 | N/A | 219 | N/A |
9/30/2014 | 11,177 | 465 | N/A | 338 | N/A |
6/30/2014 | 10,824 | 457 | N/A | 240 | N/A |
3/31/2014 | 10,408 | 431 | N/A | 204 | N/A |
12/31/2013 | 10,081 | 412 | N/A | 186 | N/A |
9/30/2013 | 9,667 | 384 | N/A | 221 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 600511's forecast earnings growth (11.4% per year) is above the savings rate (2.9%).
Earnings vs Market: 600511's earnings (11.4% per year) are forecast to grow slower than the CN market (23.2% per year).
High Growth Earnings: 600511's earnings are forecast to grow, but not significantly.
Revenue vs Market: 600511's revenue (10.1% per year) is forecast to grow slower than the CN market (13.3% per year).
High Growth Revenue: 600511's revenue (10.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 600511's Return on Equity is forecast to be low in 3 years time (13.7%).